<DOC>
	<DOCNO>NCT02106442</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( endpoint : frequency bone fracture , percent change bone density , etc . ) safety administration sodium risedronate tablet ( Benet 75 mg Tablets ) 36 month osteoporosis patient daily medical practice .</brief_summary>
	<brief_title>36-month Special Drug Use Surveillance Frequency Bone Fractures With Sodium Risedronate Tablets</brief_title>
	<detailed_description>This special drug use surveillance design evaluate efficacy ( endpoint : frequency bone fracture , percent change baseline bone density , etc . ) safety sodium risedronate tablet ( Benet 75 mg Tablets ) osteoporosis patient daily medical practice . The usual dosage adult 75 mg sodium risedronate administer orally sufficient volume ( approximately 180 mL ) water monthly waking . For least 30 minute administration , patient avoid lie supine position avoid take food , drink ( except water ) oral drug . For detail , see `` Precautions related dosage administration '' section package insert .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Osteoporosis patient meet follow criterion : 1 . Patients 1 4 confirmed vertebral body fracture T4L4 region thoracic lumbar spine Xray examination screening ( within 3 month start administration Benet 75 mg Tablets ) 2 . Male postmenopausal female patient age 50 year old 3 . Ambulatory outpatient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>